Press Releases

18 Dec 2015The Medicines Company Agrees to Divest its Hemostasis Portfolio to Mallinckrodt plc15 Dec 2015The Medicines Company Announces Investigational Lipid Modulating Agent, MDCO-216, Phase 1 Data Published in European Heart Journal- Cardiovascular Pharmacotherapy09 Dec 2015Glenn Sblendorio To Retire as President and Chief Financial Officer from The Medicines Company04 Dec 2015The Medicines Company to Participate in Oppenheimer 26th Annual Healthcare Conference20 Nov 2015The Medicines Company Receives European Commission Approval for IONSYS® 40 micrograms per dose transdermal system (fentanyl) to Treat Post-Operative Pain in Adult Hospitalized Patients13 Nov 2015Federal Circuit overturns District Court decision on Angiomax patents; Grants The Medicines Company’s request for rehearing of appeal11 Nov 2015Alnylam Pharmaceuticals and The Medicines Company Announce that New ALN-PCSsc Results from Late-Breaking Presentation at American Heart Association Meeting Confirm Potential for Bi-Annual Hypercholesterolemia Dose Regimen05 Nov 2015The Medicines Company To Present New Data on Cardiovascular Portfolio at American Heart Association (AHA) Scientific Sessions03 Nov 2015The Medicines Company Reports Third-Quarter and First Nine Months 2015 Business and Financial Results26 Oct 2015Results of First-in-Man Study with Investigational Anesthetic ABP-700 Presented at ANESTHESIOLOGY® 2015 and International Society of Anesthetic Pharmacology Annual Meetings22 Oct 2015The Medicines Company To Present Data on Potentially Innovative Surgical Anesthetic at American Society of Anesthesiologists 2015 Meeting16 Oct 2015The Medicines Company to Announce Third Quarter 2015 Financial Results on Tuesday, November 3, 201506 Oct 2015The Medicines Company and SymBio Pharmaceuticals Establish Strategic Partnership for IONSYS® (fentanyl iontophoretic transdermal system) in Japan01 Oct 2015The Medicines Company Announces BARDA Exercises Next Option on Contract for Support of the Development of CARBAVANCE® (meropenem/RPX7009) for Drug-Resistant Gram-Negative Pathogens01 Oct 2015The Medicines Company Announces Participation at IDWeek 2015 Meeting25 Sep 2015The Medicines Company Receives CHMP Positive Opinion for IONSYS® to Treat Post-operative Pain in Adult Patients18 Sep 2015The Medicines Company Reports Discovery of New Series of Beta-Lactamase Inhibitors at ICAAC/ICC 201518 Sep 2015New Treatment Options for Carbapenem-Resistant Enterobacteriaceae (CRE) Infection Needed, According to Study by The Medicines Company15 Sep 2015The Medicines Company Announces Participation at ICAAC/ICC 2015 Meeting01 Sep 2015Analysis from CHAMPION PHOENIX Trial Highlight the Efficacy of Cangrelor among Patients undergoing PCI via the Radial Approach01 Sep 2015MATRIX Trial Results Presented at Hot Line Session of ESC Congress 2015 and Simultaneously Published in The New England Journal of Medicine31 Aug 2015The Medicines Company Appoints Dr. Fred Eshelman as Non-Executive Chairman of the Board24 Aug 2015The Medicines Company Announces Participation at 2015 European Society of Cardiology (ESC) Congress in London29 Jul 2015The Medicines Company Reports Second-Quarter and First-Half 2015 Financial Results13 Jul 2015The Medicines Company to Announce Second Quarter Financial Results on Wednesday July 29, 201509 Jul 2015The Medicines Company Authorizes Generic Launch of ANGIOMAX® (bivalirudin)02 Jul 2015Federal Circuit Rules Against The Medicines Company in Angiomax® (bivalirudin) Patent Litigation22 Jun 2015The Medicines Company Announces FDA Approval of KENGREAL™ (cangrelor) as an Adjunct to Percutaneous Coronary Intervention (PCI) for Reducing Thrombotic Events01 Jun 2015The Medicines Company to Hold Conference Call on Tuesday, June 2 to Discuss Clinical Trial Results of ABP-700 and MDCO-21601 Jun 2015The Medicines Company Announces Results of Phase 1 Study for Novel Investigational Intravenous Anesthetic, ABP-70026 May 2015The Medicines Company Presents New Data Showing Remodeling Effect of MDCO-216 on HDL Particles in Coronary Artery Disease Patients22 May 2015The Medicines Company to participate in the Jefferies 2015 Healthcare Conference07 May 2015The Medicines Company to Participate in Bank of America Merrill Lynch 2015 Health Care Conference05 May 2015The Medicines Company Reports First Quarter 2015 Financial Results and Operational Developments30 Apr 2015The Medicines Company Announces FDA Approval of RAPLIXA™ (Fibrin Sealant), the First and Only Powdered Fibrin Sealant Ready-to-Use for Mild to Moderate Surgical Bleeding30 Apr 2015The Medicines Company Announces FDA Approval of IONSYS® (fentanyl iontophoretic transdermal system) for the Management of Acute Post-Operative Pain for Adult Patients in the Hospital21 Apr 2015The Medicines Company to Announce First Quarter Financial Results on Tuesday, May 5, 201520 Apr 2015FDA Approves New Formulation of MINOCIN® (minocycline) for Injection15 Apr 2015The Medicines Company Stock Trading Halted Today15 Apr 2015FDA Advisory Committee Recommends Approval of The Medicines Company's Antiplatelet Therapy Cangrelor09 Apr 2015The Medicines Company Announces Preliminary Worldwide Net Revenue for the First Quarter of 201501 Apr 2015The Medicines Company Settles Angiomax® (Bivalirudin) Patent Litigation With Sun30 Mar 2015The Medicines Company Receives European Commission Approval for Three Hospital Acute Care Products: KENGREXAL™ (cangrelor), ORBACTIV® (oritavancin) and RAPLIXA™ (sealant powder)16 Mar 2015Independent Research Confirms Reduction in Mortality and Bleeding Associated with Bivalirudin in High-Risk Acute Coronary Syndrome Patients Undergoing PCI11 Mar 2015The Medicines Company Announces Participation at 2015 American College of Cardiology (ACC) Scientific Sessions in San Diego27 Feb 2015The Medicines Company to Participate in Cowen 35th Annual Health Care Conference20 Feb 2015The Medicines Company to participate in 2015 RBC Capital Markets' Global Healthcare Conference18 Feb 2015The Medicines Company Reports Fourth Quarter and Full Year 2014 Financial Results05 Feb 2015The Medicines Company to participate in Leerink Global Healthcare Conference04 Feb 2015The Medicines Company to Announce Fourth Quarter and Full Year 2014 Financial Results on Wednesday, February 18, 201504 Feb 2015The Medicines Company Acquires Annovation Biopharma, Inc.23 Jan 2015The Medicines Company Receives CHMP Positive Opinions for Three Hospital Acute Care Products: KENGREXAL™ (cangrelor), ORBACTIV™ (oritavancin) and RAPLIXA™ (sealant powder)13 Jan 2015Technical Coverage on Pharma Stocks - Hospira, Auxilium Pharma, Medicines, SciClone Pharma, and Nektar Therapeutics08 Jan 2015The Medicines Company Prices $350 Million of Convertible Notes06 Jan 2015The Medicines Company Announces Intention to Offer $300 Million of Convertible Notes05 Jan 2015The Medicines Company to Participate in 33rd Annual J.P. Morgan Healthcare Conference

Contact Us

The Medicines Company
8 Sylvan Way
Parsippany, NJ 07054 USA
Tel 973 290 6000
Toll-free 800 388 1183
Global Medical Information

Human Resources
Verification of employment
Tel 973 290 6361
Fax 862 207 6361

Investors Relations

Krishna Gorti, MD
Tel 973 290 6122
krishna.gorti@themedco.com

Media Inquiries

Michael Blash
Tel 973 290 6100
michael.blash@themedco.com